CPI Aerostructures, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. CPI Aero manufactures structural aircraft parts and aerosystems and provides related engineering, supply-chain, kitting and maintenance services. It operates as one reportable segment, with substantial exposure to U.S. government and military programs.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $20.40 million | $20.20 million | $62.96 million | $59.26 million |
| Gross profit | $3.71 million | $5.33 million | $12.97 million | $12.42 million |
| Gross margin | 18.2% | 26.4% | 20.6% | 21.0% |
| Operating income | $1.17 million | $2.58 million | $4.76 million | $3.84 million |
| Net income | $0.30 million | $1.86 million | $2.44 million | $2.34 million |
| Diluted EPS | $0.02 | $0.15 | $0.19 | $0.19 |
- Q3 revenue rose 1.0%, but net income fell 83.8%. Cost of sales increased 12.3%, outpacing revenue growth; management cited supply-chain technical challenges and a more favorable contract negotiation and product mix in Q3 2022.
- Nine-month revenue increased 6.3%, primarily on higher Raytheon NGJ pod and USAF T-38 program activity. Nine-month net income grew 4.2% as reported; excluding $771,834 of 2022 severance charges, management said 2023 net income declined 21.6%.
- Nine-month contract estimate changes reduced gross profit by a net $1.01 million, versus a net favorable $2.06 million in the prior-year period.
Cash, liquidity and debt
- Cash was $2.61 million at September 30, down from $3.85 million at year-end 2022. Nine-month operating cash flow was $0.84 million, compared with $0.81 million in 2022. Investing used $0.09 million and financing used $1.98 million, mainly for debt repayments.
- Working capital was reported as $15.17 million at September 30, versus $12.90 million at December 31, 2022. Accounts receivable was $9.12 million and contract assets were $31.03 million; contract assets exceeded contract liabilities by $24.36 million.
- Revolver borrowings were $20.76 million; the term loan was fully repaid during July. The revolving facility bears interest at 12.0% as of quarter-end, is secured by company assets, and has no stated borrowing availability. The facility matures November 30, 2024, with scheduled reductions in the maximum borrowing amount. Operating lease liabilities totaled $5.57 million.
- Management stated existing resources should meet current working-capital needs for at least 12 months from issuance of the financial statements, but noted needs may vary and additional capital may not be available on acceptable terms.
Backlog, outlook and risks
- Total backlog was $502.94 million, down from $514.50 million at year-end 2022; funded backlog was $123.60 million. Approximately 98% of backlog was attributable to government and military contractors. Backlog is substantially subject to termination or rescheduling, and unfunded amounts depend on future orders and appropriations.
- Remaining performance obligations were approximately $123.6 million, with most obligations having an average duration of up to approximately three years. No specific revenue or earnings guidance was provided.
- Revenue and margins depend on estimates of costs to complete long-term contracts. Management cautioned that inaccurate estimates, program delays or cancellations, and unrecoverable upfront costs could adversely affect results and liquidity. Supply-chain, labor, inflation and interest-rate conditions are monitored; most long-term customer and supplier contracts have fixed pricing.
- Customer concentration is material: four customers represented 79% of nine-month revenue. Two customers represented 65% of accounts receivable at quarter-end.
Contingencies and controls
- The $3.6 million class-action settlement was paid from escrow in May 2023; the filing says the company’s covered litigation expenses were capped at its $750,000 insurance retention. A proposed shareholder derivative settlement includes governance reforms and $585,000 of plaintiff legal fees paid by the insurer; final court approval remained pending after an October 27, 2023 recommendation.
- Management reported disclosure controls were not effective as of September 30, 2023 because of previously identified material weaknesses in internal control over financial reporting. Remediation and testing were ongoing, with testing expected to continue into 2024.
Important facts for investors to verify
- Clarify working-capital movement: the balance-sheet figures imply an increase of approximately $2.28 million, while MD&A states an increase of $2.98 million; both state a 17.6% increase.
- Reconcile inconsistent deferred-tax valuation-allowance release disclosures: the notes cite approximately $122,500 for the nine-month period, while MD&A gives a different nine-month amount and separately cites an approximately $121,000 release in Q2.
- Monitor revolver capacity and maturity, covenant compliance, and cash conversion given low cash, no stated borrowing availability, and substantial contract assets.
- Track margin recovery, adverse contract-estimate adjustments, supply-chain execution, customer concentration, backlog funding and termination risk, derivative-litigation approval, and progress remediating material weaknesses.